Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co LtdfiledCriticalTaisho Pharmaceutical Co Ltd
Publication of ME02402BpublicationCriticalpatent/ME02402B/en
C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
C07D471/08—Bridged systems
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K31/4164—1,3-Diazoles
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K31/4164—1,3-Diazoles
A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
A61K31/4196—1,2,4-Triazoles
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/445—Non condensed piperidines, e.g. piperocaine
A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/445—Non condensed piperidines, e.g. piperocaine
A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K31/47—Quinolines; Isoquinolines
A61K31/472—Non-condensed isoquinolines, e.g. papaverine
A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K31/5375—1,4-Oxazines, e.g. morpholine
A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
A61K31/5375—1,4-Oxazines, e.g. morpholine
A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
A61K31/541—Non-condensed thiazines containing further heterocyclic rings
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K31/00—Medicinal preparations containing organic active ingredients
A61K31/33—Heterocyclic compounds
A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders
A61P17/14—Drugs for dermatological disorders for baldness or alopecia
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/08—Antiepileptics; Anticonvulsants
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P25/16—Anti-Parkinson drugs
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/22—Anxiolytics
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/24—Antidepressants
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P37/00—Drugs for immunological or allergic disorders
A61P37/02—Immunomodulators
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P9/00—Drugs for disorders of the cardiovascular system
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P9/00—Drugs for disorders of the cardiovascular system
A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P9/00—Drugs for disorders of the cardiovascular system
A61P9/12—Antihypertensives
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D233/70—One oxygen atom
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D249/12—Oxygen or sulfur atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
C07D451/06—Oxygen atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
C07D491/10—Spiro-condensed systems
C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Plural Heterocyclic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Thiazole And Isothizaole Compounds
(AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms
(AREA)
Pyrrole Compounds
(AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems
(AREA)
Abstract
Predmetni pronalazak se odnosi na jedinjenje saskeletom azola koje ima antagonističko dejstvo prema arginin-vazopresinskom(AVP) receptoru V1b, kao i na farmaceutske preparate koji sadrže navedenojedinjenje kao aktivni sastojak, posebno na sredstva za lečenje ili prevencijubolesti kao što su poremećaji raspoloženja (uključujući depresiju), anksiozni poremećaj,šizofrenija, Alchajmerova bolest, Parkinsonova bolest, Hantingtonova horeja,poremećaj ishrane, hipertenzija, gastrointestinalna bolest, zavisnost odnarkotika, epilepsija, cerebralni infarkt, cerebralna ishemija, cerebralniedem, povreda glave, zapaljenje, bolesti u vezi sa imunim sistemom i alopecija.The present invention relates to an azole saskeleton compound having an antagonistic action against arginine-vasopressin (AVP) receptor V1b, as well as pharmaceutical preparations containing said compound as an active ingredient, in particular for the treatment or prevention of diseases such as mood disorders (including depression) , anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral hemorrhage, inflammation, immune system, disease.
Claims (12)
1. Derivat azola predstavljen formulom (I): naznačen time što u formuli I R1 predstavlja atom vodonika, C1-5 alkil grupu (gde je navedena C1-5 alkil grupa opciono supstituisana jednom do trima grupama izabranim iz grupe koja se sastoji od hidroksi grupe, halogenih atoma, cijano, C3-7 cikloalkil i C1-5 alkoksi grupa), C3-7 cikloalkil grupu ili 4- do 8-člani zasićeni heterociklični prsten; R2 predstavlja atom vodonika ili C1-5 alkil grupu; R3 predstavlja aril ili heteroaril grupu (gde je navedena aril ili heteroaril grupa opciono supstituisana jednom ili dvema grupama izabranim iz grupe koja se sastoji od C1-5 alkoksi, C1-5 alkil grupe, halogenih atoma, trifluormetil, trifluormetoksi, cijano, hidroksi, difluormetoksi i C1-5 alkilsulfonil grupa); R4 i R5, koji mogu da budu isti ili različiti, predstavljaju, svaki za sebe, vodonikov atom, C1-5 alkil grupu (gde je navedena C1-5 alkil grupa opciono supstituisana jednom do trima grupama izabranim iz grupe koja se sastoji od hidroksi grupe, halogenih atoma, cijano, C3-7 cikloalkil i C1-5 alkoksi grupa), C3-7 cikloalkil grupu ili 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten koji sadrži jedan ili više azotovih, kiseonikovih ili sumporovih atoma u prstenu (navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono je supstituisan jednom ili dvema grupama izabranim iz grupe koja se sastoji od hidroksi, C1-5 alkil, C1-5 alkoksi grupa, halogenih atoma, cijano, C2-5 alkanoil i trifluormetil grupa); ili R4 i R5, zajedno sa susednim atomom azota, grade 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten koji opciono sadrži jedan ili veći broj azotovih, kiseonikovih ili sumporovih atoma u prstenu uz navedeni susedni azotov atom (navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono je supstituisan jednom ili dvema grupama izabranim iz grupe koja se sastoji od hidroksi, C1-5 alkil (gde je navedena C1-5 alkil grupa opciono supstituisana jednom ili dvema hidroksilnim grupama), C1-5 alkoksi grupa, halogenih atoma, cijano, C2-5 alkanoil, okso, aminokarbonil, mono-C1-5 alkilaminokarbonil, di-C1-5 alkilaminokarbonil, trifluormetil, amino, mono-C1-5 alkilamino, di-C1-5 alkilamino i C2-5 alkanoilamino grupa, a navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono sadrži C1-5 alkilensku grupu koja unakrsno povezuje dva različita ugljenikova atoma u prstenu), ili grade 2-oksa-6-azaspiro[3.3]hept-6-il ili 7-oksa-2-azaspiro[3.5]non-2-il; opciono supstituisani azolov prsten koji je predstavljen sledećom formulom (�): ima bilo koju od struktura iz sledeće grupe formula (II): gde Ry predstavlja atom vodonika ili C1-5 alkil grupu; X1 i X2 su takvi da i) kada je X1 prosta veza ili formula -CO-, X2 predstavlja -C1-5 alkilen ili -O-C1-5 alkilen grupu; i ii) kada je X1 formula -CONRx1, X2 predstavlja prostu vezu; Rx1 predstavlja atom vodonika ili C1-5 alkil grupu; i prsten A predstavlja benzenov prsten, 6-člani aromatični heterociklični prsten (gde su navedeni benzenov i 6-člani aromatični heterociklični prsten opciono supstituisani jednom ili dvema grupama izabranim iz grupe koja se sastoji od halogenih atoma i C1-5 alkoksi grupe), 4- do 8-člani zasićeni ili delimično nezasićeni heterociklični prsten koji sadrži jedan ili dva azotova atoma (gde je navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono supstituisan jednom okso grupom) ili C3-7 cikloalkan], ili farmaceutski prihvatljiva so navedenog derivata azola.1. An azole derivative represented by formula (I): indicated that in formula I R1 represents a hydrogen atom, a C1-5 alkyl group (where said C1-5 alkyl group is optionally substituted with one to three groups selected from the group consisting of a hydroxy group , halogen atoms, cyano, C3-7 cycloalkyl and C1-5 alkoxy groups), a C3-7 cycloalkyl group or a 4- to 8-membered saturated heterocyclic ring; R2 represents a hydrogen atom or a C1-5 alkyl group; R3 represents an aryl or heteroaryl group (where said aryl or heteroaryl group is optionally substituted with one or two groups selected from the group consisting of C1-5 alkoxy, C1-5 alkyl, halogen atoms, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, difluoromethoxy and a C1-5 alkylsulfonyl group); R 4 and R 5 , which may be the same or different, each represent a hydrogen atom, a C 1-5 alkyl group (wherein said C 1-5 alkyl group is optionally substituted with one to three groups selected from the group consisting of hydroxy , halogen atoms, cyano, C3-7 cycloalkyl and C1-5 alkoxy groups), a C3-7 cycloalkyl group or a 4- to 8-membered saturated or unsaturated heterocyclic ring containing one or more nitrogen, oxygen or sulfur atoms in the ring (listed The 4- to 8-membered saturated or unsaturated heterocyclic ring is optionally substituted with one or two groups selected from the group consisting of hydroxy, C1-5 alkyl, C1-5 alkoxy groups, halogen atoms, cyano, C2-5 alkanoyl and trifluoromethyl groups ); or R4 and R5, together with an adjacent nitrogen atom, form a 4- to 8-membered saturated or unsaturated heterocyclic ring optionally containing one or more nitrogen, oxygen, or sulfur atoms in the ring adjacent to said adjacent nitrogen atom (said 4- to 8- members of the saturated or unsaturated heterocyclic ring is optionally substituted with one or two groups selected from the group consisting of hydroxy, C1-5 alkyl (where said C1-5 alkyl group is optionally substituted with one or two hydroxyl groups), C1-5 alkoxy group, halogen atoms, cyano, C2-5 alkanoyl, oxo, aminocarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, trifluoromethyl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino and C2-5 alkanoylamino group, and said 4- to 8-membered saturated or unsaturated heterocyclic ring optionally contains a C1-5 alkylene group that cross-links two different carbon atoms in the ring), or builds 2-oxa-6-azaspiro[3.3]hept-6-yl or 7-oxa-2-azaspiro[3.5]non-2-yl; an optionally substituted azole ring represented by the following formula (�): has any of the structures from the following group of formulas (II): where Ry represents a hydrogen atom or a C1-5 alkyl group; X1 and X2 are such that i) when X1 is a simple bond or the formula -CO-, X2 represents -C1-5 alkylene or -O-C1-5 alkylene group; and ii) when X1 is the formula -CONRx1, X2 represents a simple bond; Rx1 represents a hydrogen atom or a C1-5 alkyl group; and ring A represents a benzene ring, a 6-membered aromatic heterocyclic ring (wherein said benzene and 6-membered aromatic heterocyclic ring are optionally substituted with one or two groups selected from the group consisting of halogen atoms and C1-5 alkoxy groups), 4- up to 8-membered saturated or partially unsaturated heterocyclic ring containing one or two nitrogen atoms (where said 4- to 8-membered saturated or unsaturated heterocyclic ring is optionally substituted with one oxo group) or C3-7 cycloalkane], or a pharmaceutically acceptable salt thereof azole derivatives.2. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema patentnom zahtevu 1, naznačena time što u prethodnoj formuli (I), R4 i R5, koji mogu da budu isti ili različiti, predstavljaju, svaki za sebe, vodonikov atom, C1-5 alkil grupu (gde je navedena C1-5 alkil grupa opciono supstituisana jednom do trima grupama izabranim iz grupe koja se sastoji od hidroksi grupe, halogenih atoma, cijano, C3-7 cikloalkil i C1-5 alkoksi grupa), C3-7 cikloalkil grupu ili 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten koji sadrži jedan ili više azotovih, kiseonikovih ili sumporovih atoma u prstenu (navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono je supstituisan jednom ili dvema grupama izabranim iz grupe koja se sastoji od hidroksi, C1-5 alkil, C1-5 alkoksi grupa, halogenih atoma, cijano, C2-5 alkanoil i trifluormetil grupa); ili R4 i R5, zajedno sa susednim atomom azota, grade 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten koji opciono sadrži jedan ili veći broj azotovih, kiseonikovih ili sumporovih atoma u prstenu uz navedeni susedni azotov atom (navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono je supstituisan jednom ili dvema grupama izabranim iz grupe koja se sastoji od hidroksi, C1-5 alkil (gde je navedena C1-5 alkil grupa opciono supstituisana jednom ili dvema hidroksilnim grupama), C1-5 alkoksi grupa, halogenih atoma, cijano, C2-5 alkanoil, okso, aminokarbonil, mono-C1-5 alkilaminokarbonil, di-C1-5 alkilaminokarbonil i trifluormetil grupa, a navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono sadrži C1-5 alkilensku grupu koja unakrsno povezuje dva različita ugljenikova atoma u prstenu), ili grade 2-oksa-6-azaspiro[3.3]hept-6-il ili 7-oksa-2-azaspiro[3.5]non-2-il.2. An azole derivative or its pharmaceutically acceptable salt according to patent claim 1, characterized in that in the preceding formula (I), R4 and R5, which may be the same or different, each represent a hydrogen atom, C1-5 alkyl group (wherein said C1-5 alkyl group is optionally substituted with one to three groups selected from the group consisting of hydroxy group, halogen atoms, cyano, C3-7 cycloalkyl and C1-5 alkoxy group), C3-7 cycloalkyl group or 4 - up to 8-membered saturated or unsaturated heterocyclic ring containing one or more nitrogen, oxygen or sulfur atoms in the ring (said 4- to 8-membered saturated or unsaturated heterocyclic ring is optionally substituted by one or two groups selected from the group consisting of hydroxy, C1-5 alkyl, C1-5 alkoxy group, halogen atoms, cyano, C2-5 alkanoyl and trifluoromethyl group); or R4 and R5, together with an adjacent nitrogen atom, form a 4- to 8-membered saturated or unsaturated heterocyclic ring optionally containing one or more nitrogen, oxygen, or sulfur atoms in the ring adjacent to said adjacent nitrogen atom (said 4- to 8- members of the saturated or unsaturated heterocyclic ring is optionally substituted with one or two groups selected from the group consisting of hydroxy, C1-5 alkyl (where said C1-5 alkyl group is optionally substituted with one or two hydroxyl groups), C1-5 alkoxy group, halogen atoms, cyano, C2-5 alkanoyl, oxo, aminocarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl and trifluoromethyl group, and said 4- to 8-membered saturated or unsaturated heterocyclic ring optionally contains C1-5 alkylene group that cross-links two different carbon atoms in the ring), or build 2-oxa-6-azaspiro[3.3]hept-6-yl or 7-oxa-2-azaspiro[3.5]non-2-yl.3. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema patentnim zahtevima 1 ili 2, naznačena time što u prethodnoj formuli (I), X1 predstavlja prostu vezu; X2 predstavlja -C1-5 alkilen ili -O-C1-5 alkilen grupu; i prsten A predstavlja benzenov prsten, 6-člani aromatični heterociklični prsten (gde su navedeni benzenov i 6-člani aromatični heterociklični prsten opciono supstituisani jednom ili dvema grupama izabranim iz grupe koja se sastoji od halogenih atoma i C1-5 alkoksi grupe) ili 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten koji sadrži jedan ili dva azotova atoma (gde je navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono supstituisan jednom okso grupom).3. An azole derivative or its pharmaceutically acceptable salt according to claim 1 or 2, characterized in that in the previous formula (I), X1 represents a simple bond; X2 represents -C1-5 alkylene or -O-C1-5 alkylene group; and ring A represents a benzene ring, a 6-membered aromatic heterocyclic ring (wherein said benzene and 6-membered aromatic heterocyclic ring are optionally substituted with one or two groups selected from the group consisting of halogen atoms and C1-5 alkoxy groups) or 4- to 8-membered saturated or unsaturated heterocyclic ring containing one or two nitrogen atoms (where said 4- to 8-membered saturated or unsaturated heterocyclic ring is optionally substituted with one oxo group).4. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema bilo kom od patentnih zahteva 1 do 3, naznačena time što u prethodnoj formuli (I), prsten A predstavlja benzenov prsten ili 6-člani aromatični heterociklični prsten (gde su navedeni benzenov i 6-člani aromatični heterociklični prsten opciono supstituisani jednom ili dvema grupama izabranim iz grupe koja se sastoji od halogenih atoma i C1-5 alkoksi grupe).4. An azole derivative or its pharmaceutically acceptable salt according to any one of claims 1 to 3, characterized in that in the preceding formula (I), ring A represents a benzene ring or a 6-membered aromatic heterocyclic ring (where benzene and 6- aromatic heterocyclic ring members optionally substituted with one or two groups selected from the group consisting of halogen atoms and C1-5 alkoxy groups).5. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema bilo kom od patentnih zahteva 1 do 4, naznačena time što u prethodnoj formuli (I), prsten A predstavlja benzenov prsten ili piridinski prsten (gde su navedeni benzenov prsten i piridinski prsten opciono supstituisani jednom ili dvema grupama izabranim iz grupe koja se sastoji od halogenih atoma i C1-5 alkoksi grupe).5. An azole derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that in the preceding formula (I), ring A represents a benzene ring or a pyridine ring (where said benzene ring and pyridine ring are optionally substituted by one or two groups selected from the group consisting of halogen atoms and C1-5 alkoxy groups).6. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema bilo kom od patentnih zahteva 1 do 5, naznačena time što u prethodnoj formuli (I), R1 predstavlja C1-5 alkil grupu; R2 je atom vodonika; i R3 predstavlja fenil ili piridil grupu (gde je navedena fenil ili piridil grupa opciono supstituisana jednom ili dvema grupama izabranim iz grupe koja se sastoji od C1-5 alkil, C1-5 alkoksi grupe, halogenih atoma, cijano, trifluormetil, difluormetoksi, trifluormetoksi i C1-5 alkilsulfonil grupa);6. An azole derivative or its pharmaceutically acceptable salt according to any of claims 1 to 5, characterized in that in the preceding formula (I), R1 represents a C1-5 alkyl group; R 2 is a hydrogen atom; and R3 represents a phenyl or pyridyl group (where said phenyl or pyridyl group is optionally substituted with one or two groups selected from the group consisting of C1-5 alkyl, C1-5 alkoxy, halogen atoms, cyano, trifluoromethyl, difluoromethoxy, trifluoromethoxy and C1-5 alkylsulfonyl group);7. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema bilo kom od patentnih zahteva 1 do 6, naznačena time što u prethodnoj formuli (I), opciono supstituisani azolov prsten koji je predstavljen sledećom formulom (�): ima bilo koju od struktura iz sledeće grupe formula (III): gde Ry predstavlja atom vodonika ili metil grupu.7. An azole derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, characterized in that in the preceding formula (I), the optionally substituted azole ring represented by the following formula (�): has any of the following structures groups of formula (III): where Ry represents a hydrogen atom or a methyl group.8. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema bilo kom od patentnih zahteva 1 do 7, naznačena time što u prethodnoj formuli (I), X1 predstavlja prostu vezu; X2 je etilen ili metilen grupa; i R4 i R5, zajedno sa susednim atomom azota, grade 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten koji opciono sadrži jedan ili veći broj azotovih, kiseonikovih ili sumporovih atoma u prstenu uz navedeni susedni azotov atom (navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono je supstituisan jednom ili dvema grupama izabranim iz grupe koja se sastoji od hidroksi, C1-5 alkil (gde je navedena C1-5 alkil grupa opciono supstituisana jednom ili dvema hidroksilnim grupama), C1-5 alkoksi grupa, halogenih atoma, cijano, C2-5 alkanoil, i trifluormetil grupa, a navedeni 4- do 8-člani zasićeni ili nezasićeni heterociklični prsten opciono sadrži C1-5 alkilensku grupu koja unakrsno povezuje dva različita ugljenikova atoma u prstenu), ili grade 2-oksa-6-azaspiro[3.3]hept-6-il.8. An azole derivative or its pharmaceutically acceptable salt according to any of claims 1 to 7, characterized in that in the preceding formula (I), X1 represents a simple bond; X 2 is an ethylene or methylene group; and R4 and R5, together with the adjacent nitrogen atom, form a 4- to 8-membered saturated or unsaturated heterocyclic ring optionally containing one or more nitrogen, oxygen, or sulfur atoms in the ring adjacent to said adjacent nitrogen atom (said 4- to 8- members of the saturated or unsaturated heterocyclic ring is optionally substituted with one or two groups selected from the group consisting of hydroxy, C1-5 alkyl (where said C1-5 alkyl group is optionally substituted with one or two hydroxyl groups), C1-5 alkoxy group, halogen atoms, cyano, C2-5 alkanoyl, and trifluoromethyl group, and said 4- to 8-membered saturated or unsaturated heterocyclic ring optionally contains a C1-5 alkylene group that cross-links two different carbon atoms in the ring), or build 2-oxo -6-azaspiro[3.3]hept-6-yl.9. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema bilo kom od patentnih zahteva 1 do 8, naznačena time što u prethodnoj formuli (I), R4 i R5, zajedno sa susednim atomom azota, grade 5- ili 6-člani zasićeni heterociklični prsten koji opciono sadrži jedan ili veći broj kiseonikovih atoma u prstenu uz navedeni susedni azotov atom (navedeni 6-člani zasićeni heterociklični prsten opciono je supstituisan jednom ili dvema grupama izabranim iz grupe koja se sastoji od hidroksilne i C1-5 alkil grupe, i navedeni 6-člani zasićeni heterociklični prsten opciono sadrži C1-5 alkilensku grupu koja unakrsno povezuje dva različita ugljenikova atoma u prstenu), ili grade 2-oksa-6-azaspiro[3.3]hept-6-il.9. An azole derivative or its pharmaceutically acceptable salt according to any of claims 1 to 8, characterized in that in the previous formula (I), R4 and R5, together with the adjacent nitrogen atom, form a 5- or 6-membered saturated heterocyclic ring which optionally contains one or more ring oxygen atoms with said adjacent nitrogen atom (said 6-membered saturated heterocyclic ring is optionally substituted with one or two groups selected from the group consisting of hydroxyl and C1-5 alkyl groups, and said 6- members of the saturated heterocyclic ring optionally contains a C1-5 alkylene group that cross-links two different carbon atoms in the ring), or they form 2-oxa-6-azaspiro[3.3]hept-6-yl.10. Derivat azola ili njegova farmaceutski prihvatljiva so prema prema patentnom zahtevu 1, naznačena time što je derivat azola predstavljen formulom (I) izabran iz grupe koja se sastoji od: 2-[2-(3-hlorfenil)-4-{4-[2-(piperidin-1-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-{4-[2-(morfolin-4-il)etil]fernil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-(4-{2-[3-(hidroksimetil)pirolidin-1-il]etil}fenil)-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-[2-(piperidin-1-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-[2-(morfolin-4-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-(2-(pirolidin-1-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-(4-{2-[(2R)-2-metilpirolidin-1-il]etil}fenil)-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-[2-(3-hidroksi-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-[2-(3-metoksipiperidin-1-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[4-{4-[2-(2,6-dimetilmorfolin-4-il)etil]fenil}-2-(4-fluor-3-metoksifenil)-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-[2-(3-metilpirolidin-1-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(4-fluor-3-metoksifenil)-4-{4-[2-(1,4-oksazepan-4-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[4-{4-[2-(3,5-dimetilmorfolin-4-il)etil]fenil}-2-(4-fluor-3-metoksifenil)-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-{5-[2-(morfolin-4-il)etil]piridin-2-il}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-{6-[2-(morfolin-4-il)etil]piridin-3-il}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-metoksifenil)-5-metil-4-{4-[2-(morfolin-4-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-metoksifenil)-4-{4-[2-(morfolin-4-il)etil)fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-(2-(3-hlor-4-fluorfenil)-4-{4-[2-(morfolin-4-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-metoksifenil)-4-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-{2-fluor-4-[2-(morfolin-4-il)etil)fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[2-(3-hlorfenil)-4-{4-[2-(morfolin-4-il)propil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-hlorfenil)-3-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-hlorfenil)-3-{4-[2-(morfolin-4-il)etil]fenil}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-hlorfenil)-3-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-metoksifenil)-3-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(4-fluor-3-metoksifenil)-3-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; N-terc-butil-2-[5-(3-metoksifenil)-3-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]acetamida; 2-[5-(3-hlor-4-fluorfenil)-3-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; N-terc-butil-2-[5-(3-hlorfenil)-3-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]acetamida; 2-[5-(3-hlorfenil)-3-{5-[2-(morfolin-4-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; N-terc-butil-2-[5-(3-hlorfenil)-3-{5-[2-(morfolin-4-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]acetamida; 2-[5-(3-hlor-4-fluorfenil)-3-{5-[2-(morfolin-4-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(4-fluor-3-metoksifenil)-3-{5-[2-(morfolin-4-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; N-terc-butil-2-[5-(3-metoksifenil)-3-{5-[2-(morfolin-4-il)etil]piridin-2-il}-1H-1,2,4-triazol-1-il]acetamida; 2-[5-(3-metoksifenil)-3-{4-[2-(morfolin-4-il)etil]fenil}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-metoksifenil)-3-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[3-(2-fluor-4-[2-(morfolin-4-il)etil]fenil}-5-(3-metoksifenil)-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[3-{3-fluor-4-[2-(morfolin-4-il)etil]fenil}-5-(3-metoksifenil)-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-metoksifenil)-3-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]fenil}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-metoksifenil)-3-{4-[2-(7-oksa-2-azaspiro[3.5]non-2-il)etil]fenil}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[5-(3-metoksifenil)-3-{4-[2-(2-oksa-6-azaspiro[3.3]hept-6-il)etil]fenil}-1H-1,2,4-triazol-1-il]-N-(propan-2-il)acetamida; 2-[1-(3-hlorfenil)-3-{4-[2-(morfolin-4-il)etil]fenil}-1H-1,2,4-triazol-5-il]-N-(propan-2-il)acetamida; 2-[1-(3-hlorfenil)-3-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-1H-1,2,4-triazol-5-il]-N-(propan-2-il)acetamida; 2-[5-(3-hlorfenil)-3-{4-[2-(morfolin-4-il)etil]fenil}-2-okso-2,3-dihidro-1H-imidazol-1-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-2-{4-[2-(piperidin-1-il)etil]fenil}-1,3-oksazol-5-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-2-{4-[2-(morfolin-4-il)etil]fenil}-1,3-oksazol-5-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-2-{4-[2-(2-oksa-6-azaspiro[3.3]hept-6-il)etil]fenil}-1,3-oksazol-5-il]-N-(propan-2-il)acetamida; 2-[5-(3-hlorfenil)-2-{4-[2-(piperidin-1-il)etil]fenil}-1,3-tiazol-4-il]-N-(propan-2-il)acetamida; 2-[5-(3-hlorfenil)-2-{4-[2-(morfolin-4-il)etil]fenil}-1,3-tiazol-4-il]-N-(propan-2-il)acetamida; 2-[3-(3-hlorfenil)-1-{4-[2-(piperidin-1-il)etil]fenil}-1H-pirazol-4-il]-N-(propan-2-il)acetamida; 2-[3-(3-hlorfenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-1H-pirazol-4-il]-N-(propan-2-il)acetamida; 2-[5-(3-hlorfenil)-3-{4-[2-(morfolin-4-il)etil]fenil}-1H-pirazol-1-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfeni])-1-{4-[2-(morfolin-4-il)etil]fenil}-2,5-diokso-2,5-dihidro-1H-pirol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; N-terc-butil-2-[4-(4-fluor-3-metoksifenil)-1-{4-[2-(morfolin-4-it)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(3-metoksifenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(3-metoksifenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(4-fluor-3-metoksifenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(4-fluor-3-metoksifenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(3-hlorfenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(3-hlorfenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; 2-[4-(3-hlorfenil)-1-{4-[2-(morfolin-4-il)propil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-1-{3-fluor-4-[2-(morfolin-4-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-1-{3-fluor-4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-1-{3-metoksi-4-[2-(morfolin-4-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlorfenil)-1-{3-metoksi-4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlor-4-fluorfenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlor-4-fluorfenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; N-terc-butil-2-[4-(3-hlor-4-fluorfenil)-1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(3-hlor-4-fluorfenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(3-hlor-4-fluorfenil)-1-{5-[2-(morfolin-4-il)etil]piridin-2-il}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; N-terc-butil-2-[4-(3-hlor-4-fluorfenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]piridin-2-il}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]acetamida; 2-[4-(3-hlorfenil)-1-{5-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]piridin-2-il}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-(1-{4-[2-(morfolin-4-il)etil]fenil}-5-okso-4-[3-(trifluormetil)fenil]-4,5-dihidro-1H-1,2,4-triazol-3-il)-N-(propan-2-il)acetamida; 2-[4-(3-hlor-4-fluorfenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)propil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(4-fluor-3-metoksifenil)-1-{4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil)-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(4-fluor-3-metoksifenil)-1-{3-metoksi-4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[1-{3-metoksi-4-[2-(3-oksa-8-azabiciklo[3.2.1]okt-8-il)etil]fenil}-4-(3-metoksifenil)-5-okso-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlor-4-fluorfenil)-5-okso-1-{4-[2-(pirolidin-1-il)etil]fenil}-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; 2-[4-(3-hlor-4-fluorfenil)-5-okso-1-{4-[2-(piperidin-1-il)etil]fenil}-4,5-dihidro-1H-1,2,4-triazol-3-il]-N-(propan-2-il)acetamida; i 2-[2-(3-hlorfenil)-4-{4-[2-(2-oksa-6-azaspiro[3.3]hept-6-il)etil]fenil}-1H-imidazol-1-il]-N-(propan-2-il)acetamida.10. An azole derivative or its pharmaceutically acceptable derivative according to claim 1, characterized in that it is an azole derivative represented by formula (I) selected from the group consisting of: 2-[2-(3-chlorophenyl)-4-{4- [2-(piperidin-1-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamide; 2-[2-(3-chlorophenyl)-4-{4-[2-(morpholin-4-yl)ethyl]fernyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamida ; 2-[2-(3-chlorophenyl)-4-(4-{2-[3-(hydroxymethyl)pyrrolidin-1-yl]ethyl}phenyl)-1H-imidazol-1-yl]-N-(propane- 2-yl)acetamide; 2-[2-(3-chlorophenyl)-4-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-1H-imidazol-1-yl ]-N-(propan-2-yl)acetamide; 2-[2-(4-fluoro-3-methoxyphenyl)-4-{4-[2-(piperidin-1-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propane-2 -yl)acetamide; 2-[2-(4-fluoro-3-methoxyphenyl)-4-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propane-2 -yl)acetamide; 2-[2-(4-fluoro-3-methoxyphenyl)-4-{4-(2-(pyrrolidin-1-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propane-2 -yl)acetamida; 2-[2-(4-fluoro-3-methoxyphenyl)-4-(4-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}phenyl)-1H-imidazole- 1-yl]-N-(propan-2-yl)acetamida;2-[2-(4-fluoro-3-methoxyphenyl)-4-{4-[2-(3-hydroxy-8-azabicyclo[3.2. 1]oct-8-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamida;2-[2-(4-fluoro-3-methoxyphenyl)-4- {4-[2-(3-methoxypiperidin-1-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamida;2-[4-{4-[2 -(2,6-dimethylmorpholin-4-yl)ethyl]phenyl}-2-(4-fluoro-3-methoxyphenyl)-1H-imidazol-1-yl]-N-(propan-2-yl)acetamide; 2 -[2-(4-fluoro-3-methoxyphenyl)-4-{4-[2-(3-methylpyrrolidin-1-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propane- 2-yl)acetamida; 2-[2-(4-fluoro-3-methoxyphenyl)-4-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl] phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamida;2-[2-(4-fluoro-3-methoxyphenyl)-4-{4-[2-(1,4 -oxazepan-4-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamida;2-[4-{4-[2-(3,5-dimethylmorpholin- 4-yl)ethyl]phenyl}-2-(4-fluoro-3-methoxyphenyl)-1H-imidazol-1-yl]-N-(propan-2-yl)acetamide; 2-[2-(3-chlorophenyl)-4-{5-[2-(morpholin-4-yl)ethyl]pyridin-2-yl}-1H-imidazol-1-yl]-N-(propan-2 -yl)acetamide; 2-[2-(3-chlorophenyl)-4-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]pyridin-2-yl}-1H-imidazole -1-yl]-N-(propan-2-yl)acetamide; 2-[2-(3-chlorophenyl)-4-{6-[2-(morpholin-4-yl)ethyl]pyridin-3-yl}-1H-imidazol-1-yl]-N-(propan-2 -yl)acetamide; 2-[2-(3-methoxyphenyl)-5-methyl-4-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propane-2 -yl)acetamide; 2-[2-(3-methoxyphenyl)-4-{4-[2-(morpholin-4-yl)ethyl)phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamida ; 2-(2-(3-chloro-4-fluorophenyl)-4-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-imidazol-1-yl]-N-(propane-2 -yl)acetamida; 2-[2-(3-methoxyphenyl)-4-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-1H- imidazol-1-yl]-N-(propan-2-yl)acetamida;2-[2-(3-chlorophenyl)-4-{2-fluoro-4-[2-(morpholin-4-yl)ethyl) phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamide; 2-[2-(3-chlorophenyl)-4-{4-[2-(morpholin-4-yl)propyl]phenyl}-1H-imidazol-1-yl]-N-(propan-2-yl)acetamida ; 2-[5-(3-chlorophenyl)-3-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-1H-1,2,4 -triazol-1-yl]-N-(propan-2-yl)acetamide; 2-[5-(3-chlorophenyl)-3-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-1,2,4-triazol-1-yl]-N-(propane -2-yl)acetamide; 2-[5-(3-chlorophenyl)-3-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]pyridin-2-yl}-1H-1 ,2,4-triazol-1-yl]-N-(propan-2-yl)acetamide; 2-[5-(3-methoxyphenyl)-3-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]pyridin-2-yl}-1H-1 ,2,4-triazol-1-yl]-N-(propan-2-yl)acetamide; 2-[5-(4-fluoro-3-methoxyphenyl)-3-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]pyridin-2-yl} -1H-1,2,4-triazol-1-yl]-N-(propan-2-yl)acetamide; N-tert-butyl-2-[5-(3-methoxyphenyl)-3-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]pyridin-2- 11}-1H-1,2,4-triazol-1-yl]acetamide; 2-[5-(3-chloro-4-fluorophenyl)-3-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]pyridin-2-yl} -1H-1,2,4-triazol-1-yl]-N-(propan-2-yl)acetamide; N-tert-butyl-2-[5-(3-chlorophenyl)-3-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]pyridin-2- 11}-1H-1,2,4-triazol-1-yl]acetamide; 2-[5-(3-chlorophenyl)-3-{5-[2-(morpholin-4-yl)ethyl]pyridin-2-yl}-1H-1,2,4-triazol-1-yl]- N-(propan-2-yl)acetamide; N-tert-butyl-2-[5-(3-chlorophenyl)-3-{5-[2-(morpholin-4-yl)ethyl]pyridin-2-yl}-1H-1,2,4-triazole -1-yl]acetamide; 2-[5-(3-chloro-4-fluorophenyl)-3-{5-[2-(morpholin-4-yl)ethyl]pyridin-2-yl}-1H-1,2,4-triazol-1 -yl]-N-(propan-2-yl)acetamide; 2-[5-(4-fluoro-3-methoxyphenyl)-3-{5-[2-(morpholin-4-yl)ethyl]pyridin-2-yl}-1H-1,2,4-triazol-1 -yl]-N-(propan-2-yl)acetamide; N-tert-butyl-2-[5-(3-methoxyphenyl)-3-{5-[2-(morpholin-4-yl)ethyl]pyridin-2-yl}-1H-1,2,4-triazole -1-yl]acetamide; 2-[5-(3-methoxyphenyl)-3-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-1,2,4-triazol-1-yl]-N-(propane -2-yl)acetamide; 2-[5-(3-methoxyphenyl)-3-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-1H-1,2,4 -triazol-1-yl]-N-(propan-2-yl)acetamide; 2-[3-(2-fluoro-4-[2-(morpholin-4-yl)ethyl]phenyl}-5-(3-methoxyphenyl)-1H-1,2,4-triazol-1-yl]- N-(propan-2-yl)acetamida; 2-[3-{3-fluoro-4-[2-(morpholin-4-yl)ethyl]phenyl}-5-(3-methoxyphenyl)-1H-1, 2,4-triazol-1-yl]-N-(propan-2-yl)acetamida;2-[5-(3-methoxyphenyl)-3-{4-[2-(3-oxa-8-azabicyclo[ 3.2.1]oct-8-yl)propyl]phenyl}-1H-1,2,4-triazol-1-yl]-N-(propan-2-yl)acetamida; 2-[5-(3-methoxyphenyl) )-3-{4-[2-(7-oxa-2-azaspiro[3.5]non-2-yl)ethyl]phenyl}-1H-1,2,4-triazol-1-yl]-N-( propan-2-yl)acetamida; 2-[5-(3-methoxyphenyl)-3-{4-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethyl]phenyl}-1H -1,2,4-triazol-1-yl]-N-(propan-2-yl)acetamida;2-[1-(3-chlorophenyl)-3-{4-[2-(morpholin-4-yl )ethyl]phenyl}-1H-1,2,4-triazol-5-yl]-N-(propan-2-yl)acetamida;2-[1-(3-chlorophenyl)-3-{4-[2 -(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-1H-1,2,4-triazol-5-yl]-N-(propan-2-yl)acetamida 2-[5-(3-chlorophenyl)-3-{4-[2-(morpholin-4-yl)ethyl]phenyl}-2-oxo-2,3-dihydro-1H-imidazol-1-yl] -N-(propan-2-yl)acetamida;2-[4-(3-chlorophenyl)-2-{4-[2-(piperidin-1-yl)ethyl]phenyl}-1,3-oxazol-5 -yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-2-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1,3-oxazol-5-yl]-N-(propan-2-yl )acetamide; 2-[4-(3-chlorophenyl)-2-{4-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethyl]phenyl}-1,3-oxazol-5-yl ]-N-(propan-2-yl)acetamide; 2-[5-(3-chlorophenyl)-2-{4-[2-(piperidin-1-yl)ethyl]phenyl}-1,3-thiazol-4-yl]-N-(propan-2-yl )acetamide; 2-[5-(3-chlorophenyl)-2-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1,3-thiazol-4-yl]-N-(propan-2-yl )acetamide; 2-[3-(3-chlorophenyl)-1-{4-[2-(piperidin-1-yl)ethyl]phenyl}-1H-pyrazol-4-yl]-N-(propan-2-yl)acetamide ; 2-[3-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-pyrazol-4-yl]-N-(propan-2-yl)acetamide ; 2-[5-(3-chlorophenyl)-3-{4-[2-(morpholin-4-yl)ethyl]phenyl}-1H-pyrazol-1-yl]-N-(propan-2-yl)acetamide ; 2-[4-(3-chlorpheni])-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-2,5-dioxo-2,5-dihydro-1H-pyrrol-3- 11]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazole -3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-5-oxo-4,5 -dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; N-tert-butyl-2-[4-(4-fluoro-3-methoxyphenyl)-1-{4-[2-(morpholin-4-it)ethyl]phenyl}-5-oxo-4,5-dihydro -1H-1,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(3-methoxyphenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4,5-dihydro-1H-1 ,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(3-methoxyphenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-5 -oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(4-fluoro-3-methoxyphenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl] phenyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(4-fluoro-3-methoxyphenyl)-1-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl] pyridin-2-yl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4,5-dihydro-1H-1 ,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(3-chlorophenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-5 -oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]acetamide; 2-[4-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)propyl]phenyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazole -3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)propyl]phenyl}-5-oxo-4,5 -dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-1-{3-fluoro-4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4,5-dihydro-1H-1,2 ,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-1-{3-fluoro-4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-5-oxo -4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-1-{3-methoxy-4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4,5-dihydro-1H-1,2 ,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chlorophenyl)-1-{3-methoxy-4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-5-oxo -4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chloro-4-fluorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4,5-dihydro-1H-1,2 ,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chloro-4-fluorophenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-5-oxo -4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; N-tert-butyl-2-[4-(3-chloro-4-fluorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4,5-dihydro -1H-1,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(3-chloro-4-fluorophenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl] phenyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(3-chloro-4-fluorophenyl)-1-{5-[2-(morpholin-4-yl)ethyl]pyridin-2-yl}-5-oxo-4 ,5-dihydro-1H-1,2,4-triazol-3-yl]acetamide; N-tert-butyl-2-[4-(3-chloro-4-fluorophenyl)-1-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl] pyridin-2-yl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]acetamide; 2-[4-(3-chlorophenyl)-1-{5-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)propyl]pyridin-2-yl}-5-oxo -4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-(1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-4-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1H-1,2, 4-triazol-3-yl)-N-(propan-2-yl)acetamide; 2-[4-(3-chloro-4-fluorophenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)propyl]phenyl}-5-oxo -4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(4-fluoro-3-methoxyphenyl)-1-{4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl)-5-oxo -4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(4-fluoro-3-methoxyphenyl)-1-{3-methoxy-4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl} -5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[1-{3-methoxy-4-[2-(3-oxa-8-azabicyclo[3.2.1]oct-8-yl)ethyl]phenyl}-4-(3-methoxyphenyl)-5-oxo -4,5-dihydro-1H-1,2,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chloro-4-fluorophenyl)-5-oxo-1-{4-[2-(pyrrolidin-1-yl)ethyl]phenyl}-4,5-dihydro-1H-1,2 ,4-triazol-3-yl]-N-(propan-2-yl)acetamide; 2-[4-(3-chloro-4-fluorophenyl)-5-oxo-1-{4-[2-(piperidin-1-yl)ethyl]phenyl}-4,5-dihydro-1H-1,2 ,4-triazol-3-yl]-N-(propan-2-yl)acetamide; i 2-[2-(3-chlorophenyl)-4-{4-[2-(2-oxa-6-azaspiro[3.3]hept-6-yl)ethyl]phenyl}-1H-imidazol-1-yl] -N-(propan-2-yl)acetamide.11. Farmaceutski preparat naznačen time što sadrži navedeni derivat azola ili njegovu farmaceutski prihvatljivu so iz bilo kog od patentnih zahteva 1 do 10 kao aktivni sastojak.11. Pharmaceutical preparation characterized in that it contains the specified azole derivative or its pharmaceutically acceptable salt from any of claims 1 to 10 as an active ingredient.12. Sredstvo za lečenje ili prevenciju bolesti kao što su poremećaj raspoloženja, anksiozni poremećaj, šizofrenija, Alchajmerova bolest, Parkinsonova bolest, Hantingtonova horeja, poremećaj ishrane, hipertenzija, gastrointestinalna bolest, zavisnost od narkotika, epilepsija, cerebralni infarkt, cerebralna ishemija, cerebralni edem, povreda glave, zapaljenje, bolesti u vezi sa imunim sistemom i alopecija, naznačeno time što sadrži derivat azola ili njegovu farmaceutski prihvatljivu iz bilo kog od patentnih zahteva 1 do 10 kao aktivni sastojak.12. Means for the treatment or prevention of diseases such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema , head injury, inflammation, diseases related to the immune system and alopecia, characterized in that it contains an azole derivative or a pharmaceutically acceptable one thereof from any one of claims 1 to 10 as an active ingredient.
Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский химико-технологический университет имени Д.И. Менделеева"
Method of producing alkyl 2-[([1,1'-biphenyl]-4-carbonyl)amino]-3-(1h-azol-1-yl) propanoates
Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound